Business context and reporting period
Intuitive Surgical, Inc. (Nasdaq: ISRG) filed this Form 10-K for the fiscal year ended December 31, 2023. The filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary. The company develops and sells da Vinci robotic surgical systems, Ion endoluminal systems, instruments and accessories, and related services. It operates as one reportable segment.
Revenue is generated from system placements and recurring instruments, accessories, service, and operating-lease revenue. Recurring revenue was 83% of total revenue in 2023. The company estimates approximately 2.286 million da Vinci procedures and 54,000 Ion biopsy procedures were performed during the year.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Total revenue | $7.124 billion | $6.222 billion | +14% |
| Instruments and accessories revenue | $4.277 billion | $3.518 billion | +22% |
| Systems revenue | $1.680 billion | $1.680 billion | Flat |
| Service revenue | $1.168 billion | $1.024 billion | +14% |
| Gross profit / gross margin | $4.730 billion / 66.4% | $4.196 billion / 67.4% | Margin down 1.0 percentage point |
| Operating income / margin | $1.767 billion / 24.8% | $1.577 billion / 25.3% | Income +12% |
| Net income attributable to Intuitive | $1.798 billion | $1.322 billion | +36% |
| Diluted EPS | $5.03 | $3.65 | +38% |
| Cash provided by operating activities | $1.814 billion | $1.491 billion | +$323 million |
| Cash, cash equivalents and investments | $7.34 billion | $6.74 billion | +$0.60 billion |
Cash and investments comprised $2.750 billion cash and equivalents, $2.473 billion short-term investments, and $2.120 billion long-term investments at year-end. Capital expenditures were $1.064 billion. The company reported no borrowing line in the balance sheet; it did report $89.8 million of lessee operating-lease liabilities. Current assets were $7.888 billion versus current liabilities of $1.659 billion.
Material changes versus the prior comparable period
- Revenue growth was led by instruments and accessories, reflecting 22% growth in da Vinci procedures and higher pricing; systems revenue stayed flat.
- Da Vinci procedures grew 22%, to approximately 2.286 million; the installed base increased 14% to 8,606 systems. Ion procedures increased 129% to approximately 54,000, and its installed base rose 66% to 534 systems.
- Systems revenue was affected by more placements under operating leases, lower sales-type lease revenue, lower average selling prices, and a higher operating-lease mix. Da Vinci placements rose to 1,370 from 1,264, while average selling price for qualifying system sales fell to approximately $1.42 million from $1.49 million.
- Gross margin declined, principally from new-product mix, higher scrap and component costs, increased inventory reserves, and lower da Vinci system ASPs; higher instruments and accessories pricing partly offset the pressure.
- Net income rose faster than operating income in part because the effective tax rate fell to approximately 7.2% from 16.3%. Swiss deferred-tax benefits and remeasurement contributed significantly to the lower 2023 tax expense.
- Inventory increased by $327 million on the balance sheet; the cash-flow discussion cites a $713 million use of cash from inventory changes, including equipment transfers. Capital expenditures increased to $1.064 billion from $532 million.
Outlook, management commentary, risks and unusual items
- Management expects 2024 capital expenditures of $1.0–$1.2 billion, mainly for facilities, funded from operating cash flow. It provided no specific 2024 revenue or earnings guidance in the supplied filing text.
- Management expects substantial research and development investment to continue and anticipates R&D expense to increase. It describes hospital capital spending as pressured and expects customers to remain cautious while macroeconomic conditions are challenging.
- Supply constraints improved during 2023, but some component costs remained elevated. Management said these constraints had not materially affected results or deliveries to date, while warning that future constraints could delay deliveries or defer procedures.
- China system placements faced tender delays associated with a healthcare-sector anti-corruption campaign. China’s 2023 quota permits 559 new surgical robots across manufacturers; Intuitive had placed 76 da Vinci systems under that quota by year-end. The effects of tender delays and provincial limits on procedure charges remain uncertain.
- Product competition, hospital reimbursement and affordability, staffing and capital constraints, supplier concentration, regulatory approvals, foreign exchange, cyber and privacy risks, and geopolitical conflicts are material risks. Weight-loss drugs have adversely affected bariatric procedure growth; management says the longer-term impact is uncertain.
- Unusual items include a $40 million fourth-quarter charitable contribution to the Intuitive Foundation and Swiss tax benefits, including a $67.1 million one-time deferred-tax remeasurement benefit. The company also recognized $598 million of share-based compensation expense.
- Legal matters include product-liability claims and ongoing patent and antitrust litigation. The company could not estimate potential loss beyond amounts recognized for certain cases. Its auditor identified estimates of standalone selling prices in system sale arrangements as a critical audit matter; the audit opinion on the financial statements and internal controls was unqualified.
Important facts for investors to verify
- Review the full-year results against the company’s latest quarterly disclosures; this filing text does not isolate fourth-quarter results.
- Assess whether procedure growth and recurring revenue can sustain growth if system placements remain pressured or the system lease mix continues to rise.
- Monitor gross-margin trends, inventory levels, capital spending, and the planned $1.0–$1.2 billion 2024 capex program.
- Evaluate how much 2023 earnings growth reflects recurring operations versus the unusually low tax rate and Swiss tax benefits.
- Track China tender activity and pricing restrictions, regulatory milestones for da Vinci 5 and SP, and developments in litigation and product-liability matters.